MALVERN, Pa. & MONTREAL--(BUSINESS WIRE)--Gemin X Pharmaceuticals announced today key clinical and preclinical data from studies of two of the Company’s novel, targeted cancer therapeutics – obatoclax (GX15-070), an innovative pan-Bcl2 inhibitor; and GMX1777, a novel inhibitor of NAD+ metabolism. These data were presented during the 20th EORTC-NCI-AACR (ENA) Symposium on “Molecular Targets and Cancer Therapeutics,” being held in Geneva, Switzerland from October 21 through October 24, 2008.
